External quality control program for inter-laboratory quality control.

N Bewarder; P Müller

PubMed · 11326697

External quality control program for inter-laboratory quality control.

Abstract

BACKGROUND: The accuracy and precision of tumor marker testing is of high clinical importance requiring the implementation of effective quality control procedures in the diagnostic laboratory. An external quality control program including an inter-laboratory comparison could be of help in improving the quality of test results. MATERIALS AND METHODS: Laboratories using BIOREF reference material sent their routine internal quality control results of each monthly control period to the evaluation center for statistical analysis and inter-laboratory comparison. RESULTS: The inter-laboratory comparison showed that the mean values of test results obtained by different laboratories can vary considerably especially when different test kits are used. A comparison of test results of laboratories using the same test kit showed much better correlation but discrepancies of coefficients of variation between these laboratories were still observed. CONCLUSION: An external quality control program revealed problems in the accuracy and precision of tumor marker test results in the individual laboratory, which could serve as a basis for the improvement of test performance.

Explore related subjects

Biomarkers, Tumor Clinical Laboratory Techniques Humans Quality Control Reagent Kits, Diagnostic Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

N Bewarder, P Müller. External quality control program for inter-laboratory quality control.. https://pubmed.ncbi.nlm.nih.gov/11326697/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2022

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting.

Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications - "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.

Biomarkers, Tumor↗

PubMed2021

Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.

BACKGROUND: While 2-4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours. METHODS: Clinical and genomic data were collected from 5945 patients with lung cancers whose tumours underwent next-generation sequencing between 2015 and 2018. Patients were followed through 2020. RESULTS: In total, 127 patients with metastatic BRAF-altered lung cancers were identified: 29 tumours had Class I mutations, 59 had Class II/III alterations, and 39 had variants of unknown significance (VUS). Tumour mutation burden was higher in Class II/III than Class I-altered tumours (8.8 mutations/Mb versus 4.9, P < 0.001), but this difference was diminished when stratified by smoking status. The overall response rate to immune checkpoint inhibitors (ICI) was 9% in Class I-altered tumours and 26% in Class II/III (P = 0.25), with median time on treatment of 1.9 months in both groups. Among patients with Class I-III-altered tumours, 36-month HR for death in those who ever versus never received ICI was 1.82 (1.17-6.11). Nine patients were on ICI for >2 years (two with Class I mutations, two with Class II/III alterations, and five with VUS). CONCLUSIONS: A subset of patients with BRAF-altered lung cancers achieved durable disease control on ICI. However, collectively no significant clinical benefit was seen.

Biomarkers, Tumor↗

PubMed2002

Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis.

Liver cirrhosis is the main risk factor for the development of human hepatocellular carcinoma (HCC). In this condition, the liver and plasma suffer a drastic depletion of retinoids. This study was conducted to investigate whether any relation exists between serum retinol levels and HCC development in cirrhotics. Seventy child-Pugh class A cirrhotic patients, 16 child-Pugh class A cirrhotic patients with HCC, and 140 age- and sex-matched subjects were included in this study. At the time of enrollment, fasting blood samples were taken to determine serum retinol levels. For the following 7 years, the 70 cirrhotic patients were also followed up for the occurrence of HCC by periodic screening with ultrasonography and serum alpha-fetoprotein assays. The serum retinol levels in both cirrhotic patients and HCC patients were significantly lower than those in healthy subjects. Among the 70 cirrhotic patients, 14 HCC were detected during follow-up. The prediagnostic retinol levels were significantly lower in cirrhotic patients who developed HCC compared with patients who did not. The odds ratio of cirrhotic patients who developed HCC in the lowest tertile to highest tertile of retinol status was 6.75 (95% CI=1.26--36.0; P=0.015). Our results suggest that a state of retinoid deficiency may promote hepatocarcinogenesis in patients at high risk such as cirrhotics.

Biomarkers, Tumor↗